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Although combination chemotherapy has been studied extensively, there is no internationally accepted standard of care for patients with advanced gastric cancer [4] [5] [6] [7] . Worldwide, the combination of 5-fl uorouracil (5-FU) and cisplatin is a mainstay in the treatment of advanced gastric cancer. Recently, oral fl uoropyrimidines have been emerging as a breakthrough treatment [6] . The use of oral agents has potential advantages, from patient convenience to avoiding the need for indwelling venous access and infusion pumps [7, 8] . An oral fl uoropyrimidine, S-1, is a fourthgeneration fl uoropyrimidine containing tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate [9] . Interesting results have been accumulating in evaluating S-1 combination therapies, particularly with platinum drugs. In this study, we reviewed phase I/II studies of combination chemotherapy with S-1 and platinum in patients with metastatic or recurrent gastric cancer.
S1 + cisplatin trials in Asia
The combination of S-1 and cisplatin is logical, given the biochemical modulation it offers: the inhibition of methionine uptake into tumor cells by cisplatin results in the enhancement of 5-FU cytotoxicity [10] . Since the fi rst phase I trial of S-1 in 1997 [11] , many phase I/II studies have been conducted in Japan and have yielded promising results.
One of the notable results of the phase II studies of S-1 and cisplatin was reported by Koizumi et al. [12] . S-1 was administered daily at a dose of 80 mg/m 2 per day for 3 weeks, followed by a 2-week rest, with cisplatin at 60 mg/m 2 given on day 8. This regimen had a 5-week cycle, and the response rate was 74%. Using the same regimen, the authors of two other studies also reported high response rates, of 67% and 66.7%, respec-
Introduction
Despite the progress made in its management, advanced gastric cancer remains a challenging disease [1] . The populations of many Asian countries are at high risk for gastric cancer, and in fact, its incidence and death rate are still high in Korea [2] . Patients with gastric cancer often present with metastatic disease, and even in those with resectable disease, rates of recurrence are high. tively [13, 14] . In other studies, S-1 was fi xed at a standard dose of 80 mg/m 2 per day and the optimal dose of cisplatin was explored with different cycles, and these regimens showed antitumor activity with response rates ranging from 53% to 73% [15] [16] [17] . Toxicities were generally manageable. Leucopenia, neutropenia, anemia, and diarrhea were the most common adverse effects. As shown in Table 1 , however, the dose intensity of cisplatin in most studies was lower than the dosages that have been widely accepted as reference regimens in advanced gastric cancer (20-25 mg/m 2 per week) [12, 14, 16, 17] .
Interestingly, one of the Japanese research groups compared a 4-week-on and 2-week-off schedule with a 2-week-on and 1-week-off schedule for S-1 [18] . In the retrospective analysis, they reported that patients following the 2-week-on and 1-week-off schedule had fewer adverse reactions and improved patient compliance. They concluded that the 2-week regimen may mitigate the adverse reactions and prolong the medication period.
With this background, a phase I/II study of a 3-week combination of S-1 plus cisplatin was conducted in Korea [8] . S-1 was given daily for 2 weeks, followed by 1 week of rest, with a fi xed dose of cisplatin at 60 mg/m 2 on day 1. The starting dose of S-1 was 60 mg/m 2 per day (level 1) on day 1 to day 14, every 3 weeks. In the phase I portion of the study, the dose of S-1 was escalated by 5 mg/m 2 per dose up to 100 mg/m 2 per day (level 5) unless the maximum-tolerated dose (MTD) was achieved, with the observation of two cycles at each dose level. At level 5, two of three patients developed grade 3 nausea /vomiting or febrile neutropenia (Table 2) ; therefore, the MTD was defi ned at level 5. The recommended dose was determined to be that given at level 4 (90 mg/m 2 per day); however, in the phase II portion of the study, poor hematologic recovery in 20 patients enrolled in the study resulted in a reduction of the S-1 dose to 80 mg/m 2 . Of the total of 42 patients assessable in the phase II study, 20 achieved a partial response, indicating that the objective response rate was 47.6%. At a median follow-up duration of 12.1 months (range, 9.8-23.2 months), the median progression-free survival and median overall survival were 5.3 months and 10.0 months, respectively (Fig. 1) . The most common grade 3 or 4 hematologic toxicities were anemia and granulocytopenia, while the most common nonhematologic toxicities were asthenia and anorexia. There was no febrile neutropenia.
According to the Japanese post-marketing survey of S-1, more than half of the patients discontinued the treatment within the fi rst two treatment cycles when S-1 was given for 4 consecutive weeks followed by a 2-week rest [19] . Because most toxicity occurred during the third week of the fi rst round of administration, the provision of a drug-free interval in the third week of the drug cycle is legitimate to minimize the incidence of adverse reactions and to maximize the effi cacy. The Korean phase I/II study of a 3-week regimen of S-1 and cisplatin noted above [8] seems to be reasonable and provides an important treatment option for patients with advanced gastric cancer. 
S1 + cisplatin trials in the West
In contrast to the results seen in Japan and Korea, a daily S-1 dose of 80 mg/m 2 was intolerable in the West due to severe diarrhea [20, 21] . Phase I pharmacokinetic studies of S-1 in patients with advanced gastric cancer concluded that the MTD of S-1 was 50 mg/m 2 per day [21, 22] . The ethnic variation in the tolerable dose of S-1 is possibly explained by differences in metabolism by cytochrome P450 related to genetic polymorphisms in CYP2A6 [23] . A prospective study of S-1 is presently underway in Korea to study the genetic association of pharmacokinetics, toxicity, and CYP2A6 polymorphism. In the West, the recommended dose of cisplatin in combination with S-1 was 75 mg/m 2 on day 1 of a 4-week cycle [21] . A multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric cancer in the United States and Europe showed encouraging results with that regimen [24] . The overall response rate was 51%, with acceptable toxicity. On the basis of this phase II study [24] , there is an ongoing phase III global study called FLAGS (First-Line Advanced Gastric Cancer Study), which compares overall survival in patients receiving S-1 plus cisplatin versus those receiving 5-FU plus cisplatin.
According to the phase I/II studies of S-1 plus cisplatin in Asia and the West, the combination of S-1 plus cisplatin is highly active against advanced gastric cancer, with a favorable toxicity profi le.
Recent developments in new platinum drugs
Recently there has been renewed interest in platinumbased chemotherapy. Oxaliplatin is a third-generation platinum analog with different activity from that of cisplatin. Oxaliplatin retains activity even against some cancer cells with acquired resistance to cisplatin, with a more favorable toxicity profi le [25] . Oxaliplatin has been widely acknowledged to be active against colon cancer, particularly in combination with 5-FU.
As fi rst-line chemotherapy in patients with advanced gastric cancer, fi ve phase II studies of oxaliplatin in combination with 5-FU have yielded response rates in the range of 38% to 66.7% [26] [27] [28] [29] [30] . Time-toprogression and overall-survival data are similar in these trials. Four of these trials studied combinations of oxaliplatin and 5-FU and leucovorin, while irinotecan was also added in one study (Table 3 ). The safety profi le of the 5-FU/oxaliplatin regimen is favorable, with low rates of grade 3-4 toxicities.
More recently, Al-Batran et al. [31] reported the results of a phase III trial comparing 5-FU-leucovorinoxaliplatin (FLO) with 5-FU-leucovorin-cisplatin (FLC), showing response rate and time-to-progression endpoints, as well as toxicity levels, favoring the FLO arm. This suggests that oxaliplatin can be substituted for cisplatin as fi rst-line therapy.
S1 + oxaliplatin
In Korea, a phase I/II study of S-1 plus oxaliplatin in three cycles as fi rst-line therapy in patients with recurrent and/or metastatic gastric cancer is ongoing [32] . In this study, S-1 was administered for 2 weeks followed by 1 week of rest, with oxaliplatin given on day 1. The dose of oxaliplatin was fi xed at 130 mg/m level. The MTD was not reached up to the highest dose level of S-1; therefore, the phase II study was conducted at the S-1 dose of 50 mg m 2 bid in combination with 130 mg/m 2 of oxaliplatin. A total of 47 patients were enrolled in the phase II study. Twenty-six partial responses were observed, and the objective response rate was 55.3% on an intention-to-treat basis and 60.5% in the perprotocol population. This 3-week, S-1-plusoxaliplatin regimen seems to be very promising against advanced gastric cancer.
Future directions
The Japanese Clinical Oncology Group conducted a large phase III study comparing 5-FU alone, S-1 alone, and a combination of irinotecan and cisplatin, and concluded that S-1 was not inferior to 5-FU. This result suggests that S-1 could replace intravenous 5-FU [33] . Furthermore, the combination of S-1 and cisplatin can be regarded as a new fi rst-line standard regimen for the treatment of advanced gastric cancer based on the recent results of the phase III SPIRITS trial, showing that the combination of S-1 and cisplatin was superior in regard to overall survival when compared with S-1 alone [34] . And, if the currently ongoing Western FLAGS trial demonstrates that S-1 plus cisplatin is superior to 5-FU plus cisplatin, S-1 plus cisplatin can become a global standard regimen for the treatment of advanced gastric cancer. However, the dose schedules of S-1 plus cisplatin differ among countries; Japan (5-week cycle), Korea (3-week cycle), and United States (4-week cycle), and this difference could be an obstacle to the further development of chemotherapy based on the S-1-plus-cisplatin combination. Further down the road, oxaliplatin will likely replace cisplatin as the platinum agent of choice.
As we move toward the tailoring of therapy to the individual patient, we have to consider the balance between the chemotherapy-related toxicity and each patient's quality of life. More innovative combinations with new drugs, molecular-targeted drugs in particular, will offer potential opportunities to enhance the effi cacy of combinations of S-1 and platinum agents.
